The U.S. Food and Drug Administration (FDA) has received reports of serious harm in patients who are physically dependent on opioid pain medicines suddenly having these medicines discontinued or the dose rapidly decreased. These include serious withdrawal symptoms, uncontrolled pain, psychological distress, and suicide.
Major depression, obesity and chronic pain are all linked to the effects of one protein, called FKBP51. Researchers have now developed a highly selective compound that can effectively block FKBP51 in mice, relieving chronic pain and having positive effects on diet-induced obesity and mood.
Scientists report that they are developing single-dose, longer-lasting opioid antidotes using polymer nanoparticles.
A rare disorder in which a 71-year-old woman experiences no pain or anxiety, raises questions about the links between physical and psychological pain.